請更新您的瀏覽器

您使用的瀏覽器版本較舊,已不再受支援。建議您更新瀏覽器版本,以獲得最佳使用體驗。

Eng

The CDE has Granted Breakthrough Therapy Designation to LBL-024, a Bispecific Antibody that Targets PD-L1 and 4-1BB, Developed by Leads Biolabs, for the Treatment of Extrapulmonary Neuroendocrine Carcinoma.

PR Newswire (美通社)

更新於 2024年10月09日05:50 • 發布於 2024年10月09日05:32 • PR Newswire

NANJING, China, Oct. 9, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") announced that Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation to LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by Leads Biolabs with global intellectual property rights, for the treatment of the patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC) who have progressed after receiving two or more lines of chemotherapy. The Breakthrough Therapy Designation awarded to LBL-024 stems from its remarkable clinical efficacy and safety profile in patients with advanced EP-NEC who failed in second-line and above chemotherapy. The current clinical data demonstrate that LBL-024 monotherapy has more than doubled both the Objective Response Rate (ORR) and Overall Survival (OS) compared to existing treatments for this disease.

Breakthrough Therapy refers to innovative or improved drugs that treat life-threatening conditions or significantly impact quality of life, where no effective treatment exist, or there is sufficient evidence that the therapy offers clear advantages over existing treatment options. In July 2012, the U.S. Food and Drug Administration (FDA) pioneered the "Breakthrough Therapy" review process, complementing fast track, accelerated approval, and priority review mechanisms. By accelerating the approval process and fostering closer collaboration, Breakthrough Therapy Designation facilitates faster development and market access for drugs with significant clinical potential. Historically, FDA data suggests that Breakthrough Therapy Designation can reduce time-to-market by approximately 2.5 years on average.

In July 2020, CDE officially introduced the Breakthrough Therapy Designation concept in China. Products granted Breakthrough Therapy Designation status will receive closer guidance and various forms of support to ensure that patients are provided with new treatment options as soon as possible.

Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, said "According to historical data from the China Drug Review Annual Report, only a few products are eligible for Breakthrough Therapy Designation, and even fewer have been approved. The designation for LBL-024 is another proof of the robust R&D capabilities of Leads Biolabs, and it is also a major victory for Leads Biolabs' insistence on focusing on the first-in-class product R&D strategy for the global market. Leads Biolabs will vigorously pursue the global clinical development of LBL-024, with the anticipation of offering more effective treatment options for patients with EP-NEC at the earliest opportunity."

Dr. Xiaoqiang Kang, founder, chairman and CEO of Leads Biolabs, said "The Breakthrough Therapy granted by the CDE prioritizes candidates that demonstrate exceptional clinical data, differentiated targets, and therapies with a high degree of efficacy certainty. This Designation represents the highest threshold and most prestigious qualification within China's pharmaceutical regulatory system, functioning as a crucial benchmark for uncovering valuable new drug projects. Leads Biolabs has consistently embraced differentiated innovation, and we eagerly anticipate the timely market introduction of LBL-024 as a novel immunotherapy, following the groundbreaking successes of anti-PD-1/PD-L1, CTLA-4, and LAG-3."

About LBL-024

LBL-024 is a tetravalent bispecific antibody that simultaneously targets PD-L1 and 4-1BB, serving dual functions: blocking the immunosuppressive PD-1/PD-L1 pathway, and selectively co-stimulating 4-1BB in the tumor microenvironment to enhance immune responses. The dual functions of LBL-024—lifting PD-1/PD-L1 immune inhibition and intensifying 4-1BB modulated T cell activation—synergistically enhance the anti-tumor immune response.

About EP-NEC

Neuroendocrine carcinoma (NEC) is a class of poorly differentiated, high-grade neuroendocrine neoplasms (NENs), which originate in the diffuse neuroendocrine cell system and can occur in many different sites. NEC can be categorized into pulmonary NEC and EP-NEC. EP-NEC exhibits similar highly aggressive and metastatic characteristics to small cell lung cancer (SCLC). Most patients are diagnosed at a later stage or already have distant metastases, resulting in rapid disease progression and a poor prognosis.

Currently, the primary first-line treatment for advanced EP-NEC involves platinum-based chemotherapy, achieving an overall response rate (ORR) of approximately 30% to 50%, with a median overall survival (mOS) of only approximately one year. Treatment options for advanced EP-NEC are limited, and there are no standard treatment strategies for patients who progress beyond second-line chemotherapy. These underscore the urgency to develop novel therapeutic approaches.

About Leads Biolabs

Nanjing Leads Biolabs Co., Ltd is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address underserved medical needs in oncology, autoimmune, and other severe diseases both in China and globally. Backboned by our proprietary technology platforms and robust drug development capabilities, we have curated a rationally designed and differentiated pipeline of 12 innovative drug candidates, six have successfully progressed into the clinical stage. Leads Biolabs is committed to providing safe, effective, accessible and affordable new drugs to address the unmet needs of patients around the world.

查看原始文章

Vantage Markets joins Skyline Guide 2024's Top 20 brokers - The Forex Industry's Michelin Guide

PR Newswire (美通社)

HK Acquisition Corporation Announces EGM to Approve De-SPAC Transaction with Synagistics

PR Newswire (美通社)

Xinhua Silk Road: Ex-champ Bruno Hasulyo starts new career to bolster SUP in eastern China metropolis

PR Newswire (美通社)
查看更多
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

最新內容

FISU World University Games opens in Duisburg

XINHUA

Modern Comfort Meets Nature in this São Paulo Apartment

Home Journal

SLD’s New F&B Spaces at Kai Tak Sports Park Honour Its Aviation Heritage

Home Journal

Home Journal Awards 2025 Now Open for Entry

Home Journal

Inside a Split-Level Home in Harmony with Nature

Home Journal

China deepens global IP ties with over 80 partners

XINHUA

Final call: InfoComm Asia 2025 Opens Next Week in Bangkok with 256 New Product Launches and Deep Dive into AI Integration

PR Newswire (美通社)

SW China's misty mountains produce spicy wasabi fortune

XINHUA

The future of adaptive fashion: How three Asian designers are championing inclusivity through dress

Tatler Hong Kong

ZEISS Group Appoints Martin Fischer as President and CEO of ZEISS Greater China

PR Newswire (美通社)

OceanX Appoints Florence Tan and Lynette Long to Key Leadership Roles in Partnerships and Public Engagement

PR Newswire (美通社)

Total Investment of Approx. USD 7.3 Million in Malaria and TB R&D Projects With Partners Including European Vaccine Initiative, University of Copenhagen, and University of Tübingen

PR Newswire (美通社)

Guardian Expands Access to Everyday Health and Holistic Wellness with New Mobile App

PR Newswire (美通社)

Where Heritage Lives: Celebrate SG60 with Grand Park City Hall

PR Newswire (美通社)

CNN's 'Next Stop' - Will Ripley visits Taiwan to uncover the island's way of embracing health and wellness

PR Newswire (美通社)

Tiger Brokers recognised by CNBC on World's Top FinTech Companies 2025

PR Newswire (美通社)

Shanghai's Pudong attracts more foreign investment

XINHUA

AQX announces acquisition of 100% stake in Singapore Enterprise Fibre Operator SPTel

PR Newswire (美通社)

Chinese scientists achieve breakthrough in human DNA assembly, cross-species transfer

XINHUA

Unlocking New Opportunities in Asia and the Greater Bay Area

PR Newswire (美通社)

Hong Kong Int'l Airport records solid air traffic growth in 2024/25

XINHUA

Nvidia CEO eyes "great future" in Chinese market

XINHUA

Japan logs record 21.5 million foreign visitors in H1

XINHUA

Embed Financial Group Holdings (EFGH) is pleased to announce a pivotal addition to the EFGH leadership team

PR Newswire (美通社)

Xinhua Silk Road: Ancient ethnic Chinese legacy revealing cultural fusion inscribed as UNESCO World Heritage

PR Newswire (美通社)

HSG Showcases Smart Manufacturing Power at MF-TOKYO 2025, Led by Akihiko Sugiyama

PR Newswire (美通社)

124 dead in Pakistan during 3 weeks of monsoon devastation

XINHUA

Cambodia's trade with RCEP countries reaches nearly 20 bln USD in 1st half of year

XINHUA

Xinhua Silk Road: Ancient ethnic Chinese legacy revealing cultural fusion inscribed as UNESCO World Heritage

PR Newswire (美通社)

JAR Wealth Management Pte. Ltd., the Singapore arm of JAR Capital, Accelerates Expansion into High-Growth Asian Markets with Strategic Acquisition of Lyra Capital Pte. Ltd.

PR Newswire (美通社)

National Palace Museum Centennial: DOUBLE SHOTS Reimagines Tradition for New Generations

PR Newswire (美通社)

China's booming low-altitude economy reshaping industries, daily life

XINHUA

Xinjiang's bold push empowers rural women at scale

XINHUA

Vectra AI Appoints New Vice President and General Manager for Asia Pacific & Japan

PR Newswire (美通社)

Coda Accelerates Global Expansion with Acquisition of European Payments Platform Recharge

PR Newswire (美通社)

Daily World Briefing, July 17

XINHUA

Kavalan, Golden Blue Launch 'Team Kavalan 2.0' - A Toast to South Korea's Finest Bars

PR Newswire (美通社)

Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

PR Newswire (美通社)

BEYOND Expo 2026 Returns to Macao on May 27-30, Unveiling Its Most Ambitious and Globally Connected Edition Yet

PR Newswire (美通社)

UN humanitarians say dozens killed while seeking food in Gaza

XINHUA